Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of BI 655066 in moderate to severe chronic plaque psoriasis
2014-001687-36Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in psoriasis, sponsored by Boehringer Ingelheim. Primary endpoints: PASI 90 response and Long-term safety of BI 655066. Started Jul 2014; status: terminated.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2014-001687-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001687-36.